comparemela.com

Latest Breaking News On - Joint corporate - Page 5 : comparemela.com

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 .

United-kingdom
Mary-jane-elliott
Mark-lewis
Panmure-gordon
David-deuchler
Chris-welsh
Rupert-dearden
Kumar-srinivasan
Maher-masoud
Emma-earl-freddy-crossley
Christine-fanelle
Nasdaq

Investegate | Company Announcement

Investegate announcements from Transaction in Own Shares

United-states
London
City-of
United-kingdom
America
Darren-willis
Sam-greatrex
Alan-geeves
Tom-williams
James-waterlow
Alaina-wong
Ed-orlebar

Investegate | Company Announcement

Investegate announcements from Transaction in Own Shares

London
City-of
United-kingdom
United-states
America
Robert-peel
Alan-geeves
James-waterlow
Alaina-wong
Ed-orlebar
Tom-williams
Sam-greatrex

Investegate | Company Announcement

Investegate announcements from Announcement of Joint Corporate Broker

United-kingdom
Holly-grainger
Lucy-legh
David-flin
Dan-webster
Tom-ballard
Peel-hunt
Wickes-group
Investec-bank
Joint-corporate

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood.

United-kingdom
Australia
North-carolina
United-states
Rockville
Western-australia
Sydney
New-south-wales
Mary-jane-elliott
Panmure-gordon
Rupert-dearden
David-deuchler

vimarsana © 2020. All Rights Reserved.